| Joseph James Albanese, DO | |
|
1541 Route 88, Suite A, Brick, NJ 08724-2373 | |
| (732) 836-3200 | |
| (732) 836-3201 |
| Full Name | Joseph James Albanese |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 35 Years |
| Location | 1541 Route 88, Brick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306850599 | NPI | - | NPPES |
| 7396406 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 25MB61917 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Meridian-fresenius Dialysis At Brick | Brick, NJ | Dialysis facility |
| Fmc John J De Palma Renal Center | Toms river, NJ | Dialysis facility |
| Rcg Whiting Dialysis Ctr | Whiting, NJ | Dialysis facility |
| Ronan Dialysis | Jackson, NJ | Dialysis facility |
| Community Medical Center | Toms river, NJ | Hospital |
| Ocean Medical Center | Brick, NJ | Hospital |
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Southern Ocean Medical Center | Manahawkin, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jersey Coast Nephrology And Hypertension Associates Llc | 8426009853 | 12 |
News Archive
Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study in the July 18 issue of JAMA.
What causes a virus to suddenly begin infecting large numbers of people? Scientists have long known that the process they call "viral emergence" involves a wide variety of factors. Some are changes in the environment, either generated by natural causes or human activity. Others are internal, arising from accidental changes - mutations -in the virus' genetic code.
Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
› Verified 6 days ago
| Entity Name | Jersey Coast Nephrology And Hypertension Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740204494 PECOS PAC ID: 8426009853 Enrollment ID: O20050203000056 |
News Archive
Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study in the July 18 issue of JAMA.
What causes a virus to suddenly begin infecting large numbers of people? Scientists have long known that the process they call "viral emergence" involves a wide variety of factors. Some are changes in the environment, either generated by natural causes or human activity. Others are internal, arising from accidental changes - mutations -in the virus' genetic code.
Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph James Albanese, DO 1541 Route 88, Suite A, Brick, NJ 08724-2373 Ph: (732) 836-3200 | Joseph James Albanese, DO 1541 Route 88, Suite A, Brick, NJ 08724-2373 Ph: (732) 836-3200 |
News Archive
Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study in the July 18 issue of JAMA.
What causes a virus to suddenly begin infecting large numbers of people? Scientists have long known that the process they call "viral emergence" involves a wide variety of factors. Some are changes in the environment, either generated by natural causes or human activity. Others are internal, arising from accidental changes - mutations -in the virus' genetic code.
Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
› Verified 6 days ago
Dr. Mrugesh Chhaganlal Panchani, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 210 Jack Martin Blvd Ste D1, Brick, NJ 08724 Phone: 732-458-5854 Fax: 732-458-8012 | |
Dr. Shawn Keating, Nephrology Medicare: Medicare Enrolled Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-2200 | |
Dr. Ladan Ilkhani, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 985 Cedarbridge Ave, Brick, NJ 08723 Phone: 732-477-5600 Fax: 732-477-1899 | |
Dr. Morrow C. Corvasce, MD Nephrology Medicare: Medicare Enrolled Practice Location: 329 Cedarcroft Dr, Brick, NJ 08724 Phone: 732-892-7749 Fax: 732-701-1447 | |
Dr. Jessica Bautista Seares, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 35 Beaverson Blvd Bldg 7, Suite B, Brick, NJ 08723 Phone: 732-262-2400 Fax: 732-262-3883 | |
Dr. Ariel Meyer, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 210 Jack Martin Blvd., Suite D-1, Brick, NJ 08724 Phone: 732-458-5067 Fax: 732-458-4962 | |
Dr. Ali R Moosvi, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1640 Highway 88, Suite 201, Brick, NJ 08724 Phone: 732-840-1900 Fax: 732-840-0355 |